These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1371 related articles for article (PubMed ID: 21527123)

  • 41. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial.
    Brecht S; Desaiah D; Marechal ES; Santini AM; Podhorna J; Guelfi JD
    J Clin Psychiatry; 2011 Aug; 72(8):1086-94. PubMed ID: 20868642
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.
    Kornstein SG; Fava M; Jiang Q; Tourian KA
    Psychopharmacol Bull; 2009; 42(3):21-35. PubMed ID: 19752839
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
    Pritchett YL; Marciniak MD; Corey-Lisle PK; Berzon RA; Desaiah D; Detke MJ
    J Psychiatr Res; 2007; 41(3-4):311-8. PubMed ID: 16934840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E; Fava M; Papakostas GI
    J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meta-analysis of placebo rates in major depressive disorder trials.
    Stolk P; Ten Berg MJ; Hemels ME; Einarson TR
    Ann Pharmacother; 2003 Dec; 37(12):1891-9. PubMed ID: 14632596
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
    Citrome L
    Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression.
    Krystal AD; Harsh JR; Yang R; Rippon GA; Lankford DA
    J Clin Psychiatry; 2010 Jan; 71(1):32-40. PubMed ID: 20051221
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study.
    Stamm TJ; Lewitzka U; Sauer C; Pilhatsch M; Smolka MN; Koeberle U; Adli M; Ricken R; Scherk H; Frye MA; Juckel G; Assion HJ; Gitlin M; Whybrow PC; Bauer M
    J Clin Psychiatry; 2014 Feb; 75(2):162-8. PubMed ID: 24345793
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
    Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
    J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
    Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI
    J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.
    Pangallo B; Dellva MA; D'Souza DN; Essink B; Russell J; Goldberger C
    J Psychiatr Res; 2011 Jun; 45(6):748-55. PubMed ID: 21511276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.
    Iwata N; Tourian KA; Hwang E; Mele L; Vialet C
    J Psychiatr Pract; 2013 Jan; 19(1):5-14. PubMed ID: 23334675
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug Administration.
    Gopalakrishnan M; Zhu H; Farchione TR; Mathis M; Mehta M; Uppoor R; Younis I
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32141721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Escitalopram versus placebo in the treatment of dysthymic disorder.
    Hellerstein DJ; Batchelder ST; Hyler S; Arnaout B; Toba C; Benga I; Gangure D
    Int Clin Psychopharmacol; 2010 May; 25(3):143-8. PubMed ID: 21811192
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response.
    Kobak KA; Leuchter A; DeBrota D; Engelhardt N; Williams JB; Cook IA; Leon AC; Alpert J
    J Clin Psychopharmacol; 2010 Apr; 30(2):193-7. PubMed ID: 20520295
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants.
    Mancini M; Wade AG; Perugi G; Lenox-Smith A; Schacht A
    J Psychiatr Res; 2014 Apr; 51():21-9. PubMed ID: 24462042
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.
    Dunlop BW; Reddy S; Yang L; Lubaczewski S; Focht K; Guico-Pabia CJ
    J Clin Psychopharmacol; 2011 Oct; 31(5):569-76. PubMed ID: 21869698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 69.